Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
The Dow Jones uses price weighting, which gives more influence to higher-priced stocks. This note covers the rationale and implications for investors.
25,369 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
As AI spending hits record levels, Chamath Palihapitiya argues the real test is whether buyers of AI can deliver dura...
As July 29 approaches, investors eye Microsoft’s Q4 results for a potential breakout. This article lays out why the s...
Policy clarity clears the path for road ahead build-to-rent projects, lifting investor confidence. Still, the pace of...
A retiree with $1 million eyeing Florida’s Gulf Coast weighs the no state income tax boost against housing costs, ins...
A niche bond ETF focused on mid-tier CLO tranches is drawing buyers as rate expectations stay elevated. The fund aims...
You don’t have to run every deal to build real estate wealth. This guide shows how to fire yourself still scale—deleg...
NVIDIA doubles down on its OpenAI investment strategy to secure GPU demand and influence the AI software stack, a mov...
New data released this week shows Americans facing persistent affordability pressures. Three charts highlight afforda...
As mdxhealth (MDXH) 2025 earnings unfold, investors watch cash burn, pipeline progress, and strategic partnerships. T...
A lithium-extraction startup says its new method triples recovery while shortening timelines, accelerating toward com...
Dubai's ultra-wealthy are paying record sums for private jet charters to Europe as regional tensions disrupt commerci...